Direct meta-analyses comparing the immunogenicity (rates of seroconversion *) of H1N1 influenza vaccines at higher versus next lower doses of hemagglutinin antigen (HA).

Only randomized trials were included. All doses are in µg. N = total number of subject analyzed; (ref) = References to included studies; RR = Random-effect risk ratio; CI = Confidence Intervals.1Adults = from 18 to 64 years;2Elderly = from 65 years;3Adolescents = from 10 to 17 years;4Children = from 6 months to 9 years (see Table S1 for several exceptions).*Seroconversion = subjects with a pre-vaccination hemagglutinination-inhibition antibody titer = 1∶40, or a pre-vaccination titer > = 1∶10 and an increase in the titer by a factor of four or more after vaccination.**The total sample of overall meta-analyses may be lower (higher) than the sum of stratified meta-analyses because some arms had to be split to be included in more than a stratified meta-analysis (some arms were different from the main comparisons shown in the Table). In any case, no patient was included more than once in any of the meta-analyses. Al = Only aluminum adjuvants; Sq = Only squalene-based (oil-in-water) adjuvants.本数据集仅纳入随机对照试验。所有剂量单位均为微克（µg）。N为纳入分析的受试者总例数；(ref) 代表纳入研究的参考文献；RR为随机效应风险比（Random-effect risk ratio）；CI为置信区间（Confidence Intervals）。 1 成年组：年龄范围为18至64岁； 2 老年组：年龄≥65岁； 3 青少年组：年龄范围为10至17岁； 4 儿童组：年龄范围为6个月至9岁（部分例外情况详见附表S1）。 * 血清阳转：指疫苗接种前血凝抑制抗体滴度≥1∶40，或疫苗接种前滴度≥1∶10且接种后滴度提升4倍及以上的受试者。 ** 整体荟萃分析的总样本量可能低于（或高于）分层荟萃分析的样本量之和，原因是部分研究组需拆分后才能纳入多个分层荟萃分析（部分研究组与表格中展示的主要对比组存在差异）。无论如何，无受试者在任意一项荟萃分析中被重复纳入。 Al：仅含铝佐剂；Sq：仅含角鲨烯基（油包水型）佐剂。